ADMA

Adma Biologics, Inc.

A maker of plasma-derived medicines for people with weakened immune systems, ADMA Biologics produces immune globulin therapies such as BIVIGAM and Nabi-HB, used to treat primary immunodeficiency and to guard against hepatitis B. The company was formed in 2013 when ADMA Biologics merged with Nabi Biologics, combining their plasma collection and manufacturing operations. Headquartered in Boca Raton, Florida, it collects plasma and turns it into treatments for immune deficiency patients.

CUSIP: 000899104HealthcareUS2 holders

Ownership Activity Financials Filings

ADMA

ADMA

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Other Events

Regulation FD Disclosure

Regulation FD Disclosure

Results of Operations and Financial Condition

Results of Operations and Financial Condition